Eli Lilly Covid Antibody Drug Gets Emergency FDA Clearance
By News
Published 3 years ago on
November 9, 2020
Share
[aggregation-styles]
Bloomberg Subscription
Bloomberg Subscription
Eli Lilly & Co.’s antibody therapy was granted an emergency-use authorization by U.S. drug regulators for treating Covid-19, widening access to a treatment that early data suggests is effective in keeping people infected with the coronavirus out of the hospital.
The Food and Drug Administration authorized the treatment, called bamlanivimab, for use against mild-to-moderate Covid-19 in adult and pediatric patients, the agency said on its website.
Shares of Eli Lilly gained 4.5% in late trading on Monday. Through the close, the stock had advanced 8.3% so far this year.
RELATED TOPICS:
Categories
Latest
Videos
Politics /
39 mins ago
Tabloid Publisher Says He Pledged to Be Trump Campaign’s ‘Eyes and Ears’ During 2016 Race
Business /
46 mins ago
General Motors Reports Strong First-Quarter Profits as Prices Help Offset Small US Sales Dip
Sports /
2 hours ago
Caitlin Clark Is Set to Sign a New Nike Deal Valued at $28 Million Over 8 Years, Reports Say
World /
2 hours ago
A Far-Right German EU Lawmaker’s Aide Is Arrested on Suspicion of Spying for China
Economy /
2 hours ago
Wall Street Rallies and Adds to Its Hot Start to the Week
Opinion /
3 hours ago
Newsom Criticizes Local Response to Homelessness. He Should Look in the Mirror.
